|
Allogeneic Haematopoietic Stem Cell Transplant (HSCT) for people of all ages with Sickle Cell Disease (SCD), Commissioning Policy (CP224). November 2021 (PDF, 443Kb)
|
|
Brachytherapy for the treatment of gynaecological malignancies for people aged 18 years and above, Commissioning Policy (CP75), July 2024 (PDF, 440Kb)
|
|
Cannabidiol for treating seizures caused by tuberous sclerosis complex in people aged 2 years and above (PP272) December 2026 (PDF, 249Kb)
|
|
Chimeric Antigen Receptor T Cell (CAR T) Therapy, Gilead Axicabtagene Ciloleucel (Yescarta®) Service Specification (CP175), March 2019 (PDF, 514Kb)
|
|
Chimeric Antigen Receptor T Cell (CAR T) Therapy, Novartis Tisagenlecleucel (Kymriah ®) Service Specification, (CP176), March 2019 (PDF, 571Kb)
|
|
Chimeric Antigen Receptor T Cell (CAR T) Therapy, Policy Position Statement, (PP185). April 2023 (PDF, 254Kb)
|
|
CP01, Brachytherapy for the treatment of localised prostate cancer, Commissioning Policy, November 2024 (PDF, 540Kb)
|
|
CP247, Autologous haematopoietic stem cell transplantation for people aged 18 years and over with previously treated relapsing multiple sclerosis, Commissioning Policy, November 2024 (PDF, 523Kb)
|
|
Eculizmab for Paroxysmal Nocturnal Haemoglobinuria (PNH), Commissioning Policy, (CP152), July 2024 (PDF, 779Kb)
|
|
Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (aged 2 years and above) (PP250) December 2026 (PDF, 258Kb)
|
|
Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC) in adults (PP274) December 2026 (PDF, 332Kb)
|
|
Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) (all ages) (PP273) December 2026 (PDF, 335Kb)
|
|
Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplant (BTLT) (All Ages), Policy Position Statement, (PP251), February 2023 (PDF, 288Kb)
|
|
Haematopoietic Stem Cell Transplantation (HSCT) for adults, Policy Position Statement (PPS142), January 2025 (PDF, 480Kb)
|
|
Haematopoietic stem cell transplantation for adults, Service Specification (CP79). January 2020 (PDF, 295Kb)
|
|
Hepatobiliary Surgery, Service Specification (CP73), June 2021 (PDF, 318Kb)
|
|
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (NETs), Policy Position Statement (PP195), November 2026 (PDF, 334Kb)
|
|
Lymphovenous Anastamosis (LVA) microsurgery for primary and secondary lymphoedema, Commissioning Policy (CP87b), August 2015 (PDF, 918Kb)
|
|
Lymphovenous Anastamosis (LVA) microsurgery for primary and secondary lymphoedema, Service Specification (CP87a), August 2015 (PDF, 817Kb)
|
|
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors (NET) in Adults, Service Specification, (CP266), March 2023 (PDF, 300Kb)
|
|
Plerixafor for stem cell mobilisation, Policy Position Statement (PP154), July 2024 (PDF, 208Kb)
|
|
Positron Emission Tomography (PET) (CP50), Commissioning Policy, April 2024 (PDF, 488Kb)
|
|
Positron Emission Tomography (PET), Service Specification (CP50b). September 2020 (PDF, 514Kb)
|
|
Proton Beam Therapy for adults with cancer Commissioning Policy (CP147), July 2023 (PDF, 279Kb)
|
|
Proton Beam Therapy for children, teenagers and young adults (TYA) with cancer, Commissioning Policy (CP148), April 2023 (PDF, 231Kb)
|
|
RFA for Barretts Oesophagus Service v1.0 (CP183) Review Date Ext March 2025 (PDF, 481Kb)
|
|
Salvage Cryotherapy for Prostate Cancer, Policy Position Statement, (PP173). June 2020 (PDF, 188Kb)
|
|
Selective internal radiation therapies (SIRT) for treating adults with hepatocellular carcinoma (PPS227), Policy Position Statement, November 2021 (PDF, 276Kb)
|
|
Services for Children with Cancer, Service Specification (SS86), December 2024 (PDF, 509Kb)
|
|
Soft Tissue Sarcoma, Service Specification (CP149), May 2020 (PDF, 410Kb)
|
|
Radiofrequency Ablation (RFA) for the Management of Barrett's Oesophagus, Service Specification (CP183b). May 2020 (PDF, 496Kb)
|
|
Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above (PP278) August 2026 (PDF, 511Kb)
|
|
Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above with (LANPC) (PP280) August 2026 (PDF, 371Kb)
|
|
Stereotactic Ablative Body Radiotherapy (SABR) for patients with metachronous extracranial oligometastic cancer (all ages), Commissioning Policy (CP121), December 2024 (PDF, 551Kb)
|
|
Stereotactic Ablative Body Radiotherapy (SABR) for the management of Non-Small Cell Lung Cancer in people aged 18 years and above, Commissioning Policy (CP76) June 2023 (PDF, 525Kb)
|
|
Stereotactic Ablative Body Radiotherapy (SABR), Service Specification (SS219), December 2024 (PDF, 505Kb)
|
|
Stereotactic Ablative Radiotherapy (SABR) for patients with hepatocellular carcinoma (HCC) (adults), Commissioning Policy, (CP124), December 2024 (PDF, 550Kb)
|
|
Stereotactic Ablative Radiotherapy (SABR) for people aged 18 years old and above with primary kidney cancer, Commissioning Policy (CP279), June 2024 (PDF, 512Kb)
|